Compare ENTX & SFWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ENTX | SFWL |
|---|---|---|
| Founded | 2010 | 2001 |
| Country | Israel | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Trucking Freight/Courier Services |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 147.4M | 72.7M |
| IPO Year | 2015 | 2021 |
| Metric | ENTX | SFWL |
|---|---|---|
| Price | $2.70 | $8.59 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $9.00 | N/A |
| AVG Volume (30 Days) | ★ 365.8K | 10.1K |
| Earning Date | 05-14-2026 | 03-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.22 | N/A |
| Revenue | ★ $42,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $12.73 | ★ $6.06 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.91 | $0.56 |
| 52 Week High | $4.20 | $12.00 |
| Indicator | ENTX | SFWL |
|---|---|---|
| Relative Strength Index (RSI) | 41.11 | 67.09 |
| Support Level | $1.48 | $0.78 |
| Resistance Level | $2.78 | N/A |
| Average True Range (ATR) | 0.18 | 0.69 |
| MACD | -0.04 | -0.07 |
| Stochastic Oscillator | 6.52 | 18.42 |
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.
Shengfeng Development Ltd is a holding company. Through its subsidiaries, it offers contract logistics services in China. The contract logistics services offered by the company include planning and designing supply chains, designing facilities, processing orders, collecting payments, managing inventories, and providing client services. The company's operations are based in the PRC. Its integrated logistics solutions are comprised of three business streams: B2B freight transportation services; cloud storage services; and value-added services. The company derives maximum revenue from Transportation, followed by Warehouse storage management services. The solutions provides by the company are : Internet TV; Electronic communication; Textiles and Apparel; Automotive parts; and e-commerce.